Director/PDMR Shareholding

RNS Number : 5808U

Epistem Holdings plc

03 December 2013

 

Epistem Holdings Plc ("Epistem" or the "Company")

3^rd December, 2013

Directors' shareholdings

Epistem (AIM: EHP), the biotechnology and personalised medicine company, announces that it has today been notified that the Company's Chairman, David Evans, today has acquired 18,200 ordinary shares in the Company at a price of 328.25p through his Self-Invested Personal Pension.

Following this transaction, David Evans has a beneficial holding of 98,845 ordinary shares in the Company, representing approximately 1% of the issued share capital of the Company.

For further details please contact:

Epistem Plc

Matthew Walls: Chief Executive Officer                                               [phone]

John Rylands: Finance Director                                                                 [phone]

Peel Hunt LLP

James Steel                                                                                                        [phone]

Vijay Barathan

Notes to Editors:

About Epistem

Epistem is a biotechnology and personalised medicine company commercialising its expertise in epithelial stem cells and pharmacogenomics in the areas of oncology, gastrointestinal, dermatological and infectious disease.

Epistem develops innovative therapeutics, biomarkers and diagnostics alongside providing preclinical services to drug development companies. Epistem's core expertise is focused on the regulation of adult stem cells located in epithelial tissue which includes the gastrointestinal tract, skin, hair follicles, breast and prostate. Epistem also has a range of proprietary amplification (RNA and DNA) technologies for use in drug discovery, development and diagnostics.

 

END

 

 

RDSBXBDDDBGBGXX